Advertisement

The ASCO Post Newsreels help clinicians stay up to date on news in the world of clinical oncology and hematology. Newsreels feature leading authorities presenting high-impact clinical findings at major oncology meetings throughout the year.



Showing All Recent Newsreels Videos


Advertisement

2024 NCCN Annual Conference

William J. Gradishar, MD, on HR-Positive, HER2-Negative Breast Cancer: Management Update

Natalie S. Callander, MD, on Multiple Myeloma: Management Updates

Wendy Vogel, MSN, FNP, AOCNP, FAPO, on the Evolving Role of Advanced Practice Providers in Oncology Care

Douglas B. Johnson, MD, MSCI, on Cutaneous Melanoma: Treatment Updates


2024 Society of Surgical Oncology Annual Meeting

Natália Polidorio, MD, PhD, on Triple-Negative Breast Cancer: Impact of Race on Treatment Efficacy

Heather McArthur, MD, MPH, on Early-Stage High-Risk ER+/HER2− Breast Cancer: New pCR Results for Pembrolizumab and Chemotherapy

Kerollos N. Wanis, MD, PhD, on Risks for BRCA Mutation Carriers Treated With Breast-Conserving Therapy

Akhil G. Pachimatla, MD, on NSCLC: A Link Between Image-Based Measures of Obesity and Metabolic Pathways

Judy C. Boughey, MD, on De-escalating Axillary Surgery After Chemotherapy for Breast Cancer

Jenny H. Chang, MD, on New Findings on Merkel Cell Carcinoma and Neoadjuvant Immunotherapy

Sophia McKinley, MD, EdM, on Cutaneous Melanoma: Outcomes With Adjuvant Immunotherapy


SGO 2024 Annual Meeting on Womens Cancer

Brian M. Slomovitz, MD, on Cervical Cancer: Update on Tisotumab Vedotin vs Chemotherapy

Mansoor R. Mirza, MD, on Endometrial Cancer: Update on Combination Regimen of Dostarlimab, Chemotherapy, and Niraparib

Mary McCormack, PhD, MBBS, on Locally Advanced Cervical Cancer: Results From the INTERLACE Trial

Anne Knisely, MD, on Ovarian Cancer and the Implications of Detecting Residual Disease and ctDNA

Matthew A. Powell, MD, on Endometrial Cancer: Overall Survival Update on Dostarlimab-gxly Plus Chemotherapy

Ana Oaknin, MD, PhD, on Recurrent Cervical Cancer: New Findings on Atezolizumab, Bevacizumab, and Chemotherapy


2024 Multidisciplinary Head and Neck Cancers Symposium

Nabil F. Saba, MD, on Head and Neck Cancer: Long-Term Survival Findings With Pembrolizumab and Cabozantinib

Christopher A. Barker, MD, on New Data on Vismodegib and Radiotherapy for Basal Cell Carcinoma of the Head and Neck

Nabil F. Saba, MD, on Preventing Radiation-Induced Mucositis in Patients With Squamous Cell Carcinoma of the Head and Neck

Pooja Karukonda, MD, on Coping With Financial Toxicity in Head and Neck Cancer

Evan M. Graboyes, MD, MPH, on Addressing Body Image Distress: Critical Care for Head and Neck Cancer Survivors

Evan M. Graboyes, MD, MPH, on Decreasing Delays in Adjuvant Therapy for Head and Neck Cancer

Eleni M. Rettig, MD, on HPV-Related Oropharyngeal Cancers: Early Detection and Disease Surveillance

Samuel Regan, MD, and Benjamin Rosen, PhD, on De-escalating Radiotherapy for HPV-Related Oropharyngeal Cancer

Dan P. Zandberg, MD, on Personalized Immunotherapy for HNSCC: Progress Report

Marcin R. Dzienis, MBBS, on Update on Pembrolizumab, Carboplatin, and Paclitaxel in HNSCC


2024 ASCO GU Cancers Symposium

Neeraj Agarwal, MD, on Prostate Cancer: Phase III Trial Update on Cabozantinib, Atezolizumab, and Hormonal Therapy

Maha H.A. Hussain, MD, on Prostate Cancer: New Data on Abiraterone and Prednisone Plus Olaparib

Amanda Nizam, MD, on Urothelial Carcinoma: Study Results on Enfortumab Vedotin and Avelumab

Thomas Powles, MD, on RCC: Patient-Reported Outcomes With Belzutifan vs Everolimus

Syed Muneeb Alam, MD, on Urothelial Carcinoma: Microsatellite Instability and Response to Immune Checkpoint Blockade

Umang Swami, MD, on Prostate Cancer: Differences in Genomic, Transcriptomic, and Immune Landscape Based on Site of Metastasis

Saby George, MD, on Clear Cell Kidney Cancer: Subcutaneous vs Intravenous Nivolumab

Michiel S. Van Der Heijden, MD, PhD, on Metastatic Urothelial Carcinoma: Phase III Trial Data on Enfortumab Vedotin Plus Pembrolizumab vs Chemotherapy

Enrique Grande, MD, on Adrenocortical Carcinoma: Phase II Results on Cabozantinib Plus Atezolizumab

David H. Aggen, MD, PhD, on Advanced Bladder Cancer: HER2 and PD-L1 Immunohistochemistry and HER2 Genomic Alterations

Andrew Johns, MD, on Clear Cell Renal Cell Carcinoma: Data on Tivozanib in Pretreated Patients

Thomas Powles, MD, on Clear Cell Kidney Cancer: Overall Survival Update With Adjuvant Pembrolizumab

Rohit K. Jain, MD, MPH, on Urothelial Carcinoma: New Data on Cabozantinib Plus Pembrolizumab

Andrea B. Apolo, MD, on Urothelial Carcinoma: Phase III Findings on Pembrolizumab vs Observation


2024 ASCO GI Cancers Symposium

Michael K. Gibson, MD, PhD, on Esophageal Cancer: Expert Commentary on Two Key Studies

Ken Kato, MD, PhD, on Advanced Esophageal Cancer: Biomarker Analyses From CheckMate 648

Ian Chau, MD, on Esophageal Squamous Cell Carcinoma: New Data on Nivolumab, Ipilimumab, and Chemotherapy

Manish A. Shah, MD, on Esophageal Cancer: Long-Term Outcomes of Pembrolizumab and Chemotherapy

Frank Kullmann, MD, on Metastatic Pancreatic Cancer: Recent Data on Gemcitabine and Nab-Paclitaxel

Anant Ramaswamy, DM, on Advanced Gastric Cancers: New Findings on Adding Docetaxel to Doublet

Van K. Morris, MD, on Colon Cancer: ctDNA as a Predictive Biomarker

Riccardo Lencioni, MD, on Hepatocellular Carcinoma: Transarterial Chemoembolization, Durvalumab, and Bevacizumab

Jennifer Yon-Li Wo, MD, on Colorectal and Pancreatic Cancers: New Findings on SBRT With Ipilimumab and Nivolumab

Lorraine A. Chantrill, PhD, MBBS, on Gastrointestinal Neuroendocrine Carcinomas: First-Line Treatment With Nab-Paclitaxel Plus Carboplatin

Milind M. Javle, MD, on Cholangiocarcinoma: New Data on Tinengotinib as Monotherapy

Yasunobu Ishizuka, MD, on Gastric Cancer: Does Nivolumab Infusion Time of Day Matter?

Dominik P. Modest, MD, on Colorectal Cancer: Health-Related Quality-of-Life Findings From CodeBreaK 300

Ian Chau, MD, on Gastrointestinal Cancers: Real-World Effectiveness of Nivolumab Plus Chemotherapy


2023 ASH

Jonathon B. Cohen, MD, on Mantle Cell Lymphoma: New Data on Pirtobrutinib

Danai Dima, MD, on Multiple Myeloma: Update on Safety and Efficacy of Teclistamab

Bijal D. Shah, MD, on Previously Treated Mantle Cell Lymphoma: New Findings on Brexucabtagene Autoleucel and Pirtobrutinib

Pieter Sonneveld, MD, PhD, on Newly Diagnosed Multiple Myeloma: Phase III Findings on Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone

Darren Denjay Pan, MD, on Multiple Myeloma: Inflammatory Biomarkers and Outcomes After CAR T-Cell Therapy

Mikkael A. Sekeres, MD, on Therapies for Hematologic Cancers: Is More or Less Better?

William G. Wierda, MD, PhD, on Use of Pirtobrutinib for Richter Transformation: Updated Efficacy and Safety Results

Potential Clinical Uses of Identifying New Hematologic Malignancy Predisposition Gene

Sarah C. Rutherford, MD, on Hodgkin Lymphoma: Nivolumab Plus AVD in Older Patients With Advanced-Stage Disease

Jennifer A. Woyach, MD, on CLL/SLL: 30-Month Follow-up and Subgroup Analysis of Pirtobrutinib

Michael Wang, MD, on Mantle Cell Lymphoma: New Results on Ibrutinib Plus Venetoclax

Adam S. Kittai, MD, on Richter’s Transformation: Anti-CD19 CAR T-Cell Therapy

Sara Khan, DO, on the Gender Gap in Receiving NIH Grants for Hematology Research

Sanjal H. Desai, MBBS, on Classical Hodgkin Lymphoma: Improving Outcomes With PD-1 Blockade

Andrew Srisuwananukorn, MD, on Myelofibrosis vs Essential Thrombocythemia: A Potential New Clinical Decision Tool

Jeffrey E. Rubnitz, MD, PhD, on Pediatric AML Outcomes and Racial Disparities

Mazyar Shadman, MD, MPH, on Large B-Cell Lymphoma: Autologous Transplantation vs CAR T-Cell Therapy

Harinder Gill, MD, MBBS, on Acute Promyelocytic Leukemia: Assessing the Use of Oral Arsenic Trioxide, Retinoic Acid, and Ascorbic Acid

Ibrahim Aldoss, MD, on KMT2A-Rearranged Acute Leukemia: New Data on Revumenib Monotherapy


2023 SABCS

Sara A. Hurvitz, MD, on Metastatic Breast Cancer: New Data on Tucatinib and Trastuzumab Emtansine

Amy Tiersten, MD, on Metastatic Breast Cancer: A Possible Chemotherapy-Free Front-Line Regimen

Aditya Bardia, MD, MPH, on HR-Positive, HER2-Negative Advanced Breast Cancer: New Findings on Datopotamab Deruxtecan vs Chemotherapy

Gabriel N. Hortobagyi, MD, on Early Breast Cancer: Final Invasive Disease–Free Analysis From the NATALEE Trial

Nicholas C. Turner, MD, PhD, on High-Risk Early-Stage Breast Cancer: Profiling Primary Tumors

Senthil Damodaran, MD, PhD, on Locally Advanced or Metastatic Breast Cancer: Phase II Results on Futibatinib

Daniel G. Stover, MD, on Early-Stage Breast Cancer: A Biomarker Analysis From the PALLAS Trial

Aditya Bardia, MD, MPH, on Early-Stage, High-Risk Breast Cancer: New Data on Pembrolizumab Plus Chemotherapy

Sherene Loi, MD, PhD, on Triple-Negative Breast Cancer: Phase II Study Results of Nivolumab, Carboplatin, and Paclitaxel

Sherene Loi, MD, PhD, on Biomarker Results in ER+, HER2– Primary Breast Cancer Following Neoadjuvant Chemotherapy With or Without Nivolumab

Barbara Pistilli, MD, on HR+, HER2– Advanced Breast Cancer: Update on Capivasertib Plus a CDK4/6 Inhibitor and Fulvestrant

Oleg Gluz, MD, on Response to Endocrine Therapy: Findings From the ADAPTcycle Trial

Luca Gianni, MD, on Locally Advanced, HER2-Positive Breast Cancer: New Data on Neoadjuvant Therapy and Atezolizumab

Daniel Kates-Harbeck, MD Candidate, and Nadia Harbeck, MD, PhD, on Personalizing Breast Cancer Management With AI: Novel Approach to Predicting Outcomes

Eleftherios P. Mamounas, MD, on Locoregional Irradiation, Axillary Lymph Node Involvement, and Conversion to Negative Nodes

Hope S. Rugo, MD, on Advanced Breast Cancer: Patient-Reported Outcomes From the CAPItello-291 Trial

Cynthia X. Ma, MD, PhD, on Metastatic Breast Cancer: Early Results on Copanlisib, Fulvestrant, and Abemaciclib

Peter Schmid, MD, PhD, on Early-Stage TNBC: Updated Survival Results From KEYNOTE-522

Seema Khan, MD, on Ductal Carcinoma in Situ: Central MRI and a 12-Gene Expression Assay to Optimize Local Therapy

Reshma Jagsi, MD, DPhil, on Early-Stage Breast Cancer: 5-Year Outcomes With Endocrine Therapy and Breast-Conserving Surgery

Hope S. Rugo, MD, on Triple-Negative Breast Cancer: Trial Update on Pembrolizumab Plus Olaparib vs Pembrolizumab Plus Chemotherapy


24th SUO Annual Meeting

William J. Catalona, MD, on Genetic Testing in Prostate Cancer: Expert Review

Samson W. Fine, MD, on Clinical Significance of Atypical Small Acinar and Intraductal Proliferations in the Prostate

Mark D. Tyson, MD, MPH, on High-Risk Non–Muscle-Invasive Bladder Cancer: A Potential New Treatment

Stephen J. Freedland, MD, on Managing Prostate Cancer in Transgender Women

Rana R. McKay, MD, on Mutated Prostate Cancer, PARP Inhibition, and Radical Prostatectomy

Sumanta K. Pal, MD, on Prostate Cancer: Impact of the Microbiome on Immune Therapy

Bishoy M. Faltas, MD, on Upper Tract Urothelial Carcinoma: How Biology Shapes Therapy


ESMO Congress 2023

Tina Cascone, MD, PhD, on NSCLC: Phase III Results on Nivolumab, Chemotherapy, and Surgery

Jonathan D. Spicer, MD, PhD, on Early-Stage NSCLC: Survival Results With Pembrolizumab

Ze-rui Zhao, PhD, on Resectable NSCLC: SBRT With Sequential Immunochemotherapy

Hossein Borghaei, DO, on Nonsquamous NSCLC: Findings on Sitravatinib Plus Nivolumab vs Docetaxel

Mark M. Awad, MD, PhD, on NSCLC: Neoadjuvant Nivolumab Plus Ipilimumab vs Chemotherapy

Peter Schmid, MD, PhD, on Triple-Negative Breast Cancer: Updated Results on Pembrolizumab Plus Chemotherapy

Nadia Harbeck, MD, PhD, on High-Risk Early Breast Cancer: Overall Survival Data on Abemaciclib Plus Endocrine Therapy

Benjamin Besse, MD, PhD, on NSCLC: Safety and Efficacy Data on Novel Bispecific Antibody

Jarushka Naidoo, MHS, MBBCh, on Lung Cancer: Practice-Changing Advances Reported at ESMO 2023


IASLC 2023 WCLC

Tom E. Stinchcombe, MD, on NSCLC: Strategies for Managing Secondary Primary Disease

Ticiana A. Leal, MD, on Tumor Treating Fields and Immune Checkpoint Inhibition in Metastatic NSCLC

David H. Harpole, Jr, MD, on Perioperative Durvalumab Plus Chemotherapy in Resectable NSCLC

Chee K. Lee, PhD, MBBS, on Durvalumab, Tremelimumab, and Chemotherapy in NSCLC

Yasir Y. Elamin, MD, on Brigatinib in ALK-Rearranged Metastatic Non–Small Cell Lung Cancer

Shirish M. Gadgeel, MD, on Pembrolizumab Plus Chemotherapy for Metastatic NSCLC: 5-Year Follow-up

Seshiru Nakazawa, MD, PhD, on NSCLC and Point Mutations as de Novo Oncogenic Drivers

Ilias Houda, MD, PhD Candidate, on Results of an EORTC Survey on NSCLC Resectability

Xiuning Le, MD, PhD, on Update on the Use of Tepotinib to Treat an NSCLC Subset

Gilberto de Lima Lopes, Jr, MD, MBA, on Lung Cancer Management: Expert Update

Benjamin Besse, MD, PhD, on EGFR-Mutated NSCLC: Update on Patritumab Deruxtecan in Previously Treated Disease


2023 ASCO Breakthrough Meeting

Aaron C. Tan, PhD, MBBS, on Circulating Tumor DNA: Early Biomarker of Therapeutic Response in Phase I Trials

Wei Wu, MD, PhD, on Lung Cancer: Deep Learning as a Tool for Identifying Drug-Tolerant Persister Cells

Aki Morikawa, MD, PhD, on Brain Metastases: New Findings on Predictive Drug Testing

Desheng Liang, MD, PhD, on Genetic Engineering of Mesenchymal Stem Cells for Cancer Therapy


EHA Hybrid Congress 2023

Jennifer R. Brown, MD, PhD, on CLL: Resistance to Pirtobrutinib in Pretreated Disease

Matthew J. Frank, MD, PhD, on Large B-Cell Lymphoma: New Data on CD22 CAR T-Cell Therapy

Arnon Kater, MD, PhD on CLL: Recent Data on Venetoclax, Ibrutinib, and Undetectable MRD

Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

Nikhil Munshi, MD, on Multiple Myeloma: Data From the CARTITUDE-1 Study of Ciltacabtagene Autoleucel

Nicholas J. Short, MD, on Acute Lymphoblastic Leukemia: New Analysis of Ponatinib and Blinatumomab

Nicholas J. Short, MD on Acute Lymphoblastic Leukemia: Phase II Findings on Mini-HCVD, Inotuzumab, and Blinatumomab


2023 ASCO Annual Meeting

Marie Plante, MD, on Cervical Cancer: New Data on Hysterectomy and Pelvic Node Dissection

LaQuisa C. Hill, MD, on Relapsed or Refractory T-ALL: New Data on CD5 CAR T Cells

Sebastian Stintzing, MD, on Colorectal Cancer: Influence of Liquid Biopsy in First-Line Combination Treatment

Muhit Özcan, MD, on DLBCL: Early Results on Zilovertamab Vedotin

Muhit Özcan, MD, on DLBCL: Now Recruiting Previously Untreated Patients for a Study of Zilovertamab Vedotin Plus Chemotherapy

Eunice S. Wang, MD, and Gregory Roloff, MD, on B-ALL: Outcomes With Brexucabtagene Autoleucel in Adult Patients

Claire Roddie, PhD, MBChB, on B-ALL: Safety and Efficacy Data of Obecabtagene Autoleucel

Thomas E. Hutson, DO, PharmD, on RCC: Overall Survival Analysis of Lenvatinib, Pembrolizumab, and Sunitinib

Thierry Conroy, MD, on Rectal Cancer: Long-Term Results on mFOLFIRINOX vs Preoperative Chemoradiation Therapy

Alberto Bossi, MD, on Prostate Cancer: PEACE-1 Trial Findings on Radiotherapy Plus Systemic Treatment

Tycel J. Phillips, MD, and Alex F. Herrera, MD, on DLBCL: New Data on ctDNA Status and Clinical Outcomes

Tycel J. Phillips, MD, and Alex F. Herrera, MD, on Classical Hodgkin Lymphoma: New Data on Nivolumab, AVD, and Brentuximab Vedotin

Guillermo Garcia-Manero, MD, on Myelodysplastic Syndromes: Luspatercept and Epoetin Alfa in Lower-Risk Disease

Narjust Florez, MD, and Roy S. Herbst, MD, on NSCLC: Overall Survival Analysis From the ADAURA Trial of Osimertinib

Manali K. Kamdar, MD, on Primary Refractory and Early Relapsing DLBCL: Therapeutic Options

Enrique Grande, MD, on Metastatic Urothelial Carcinoma: Updated Data From IMvigor130

Shilpa Gupta, MD, on Urothelial Carcinoma: Long-Term Outcome of Enfortumab Vedotin Plus Pembrolizumab

Bradley J. Monk, MD, on Cervical Cancer: Findings on Pembrolizumab Plus Chemotherapy

Amer Methqal Zeidan, MBBS, MHS, on Myelodysplastic Syndromes: New Data From the IMerge Study of Imetelstat

Narjust Florez, MD, and Filippo Gustavo Dall’Olio, MD, on NSCLC: New Findings on Tumor Fraction, Durvalumab, and Survival

Paula Aristizabal, MD, MAS, on Surviving Childhood Leukemia Near the Border of the United States and Mexico

Jennifer A. Ligibel, MD, on Early Breast Cancer and Weight Loss: Results From the BWEL Trial

Nagla Abdel Karim, MD, on Small Cell Lung Cancer: SWOG S1929 Results on Atezolizumab Plus Talazoparib

Tycel J. Phillips, MD, and Swetha Kambhampati, MD, on Mantle Cell Lymphoma: Real-World Outcomes With Brexucabtagene Autoleucel

Omid Hamid, MD, on Advanced Melanoma: Durable Response With Fianlimab Plus Cemiplimab

Georgina V. Long, MD, PhD, on Resected Melanoma: Biomarkers for and Efficacy of Adjuvant Nivolumab vs Placebo

Christian Pfister, MD, PhD, on Bladder Cancer: New Overall Survival Data on Perioperative Chemotherapy

Bobbie J. Rimel, MD, and Kathleen N. Moore, MD, on Ovarian Cancer: New Findings on Mirvetuximab Soravtansine vs Chemotherapy

Bobbie J. Rimel, MD, Isabelle L. Ray-Coquard, MD, PhD, on Cervical Squamous Carcinoma: Neoadjuvant Nivolumab Plus Ipilimumab

Bobbie J. Rimel, MD, and Mansoor R. Mirza, MD, on Endometrial Cancer: Patient-Reported Outcomes With Dostarlimab, Carboplatin, and Paclitaxel

Rana R. McKay, MD, and Toni K. Choueiri, MD, on RCC: New Findings on Efficacy and Safety of Atezolizumab Plus Cabozantinib

Rana R. McKay, MD, and Brian I. Rini, MD, on Clear Cell RCC: New Data From KEYNOTE-426 on Pembrolizumab Plus Axitinib vs Sunitinib

Allison Betof Warner, MD, PhD, and Adnan Khattak, PhD, MBBS, on High-Risk Resected Melanoma: Survival Results With mRNA-4157 and Pembrolizumab in KEYNOTE-942

Catherine C. Coombs, MD, on B-Cell Malignancies and Long-Term Safety of Pirtobrutinib

Funda Meric-Bernstam, MD, on HER2-Expressing Solid Tumors: Efficacy and Safety of Trastuzumab Deruxtecan

Nirav N. Shah, MD, on DLBCL: New Data on Split-Dose R-CHOP for Older Patients

Nirav N. Shah, MD, on Mantle Cell Lymphoma: Follow-up Data on Pirtobrutinib in Pretreated Disease

Lisa A. Carey, MD, and Dennis J. Slamon, MD, PhD, on Early Breast Cancer: Findings From the NATALEE Trial on Ribociclib Plus Endocrine Therapy

Lisa M. DeAngelis, MD, and Ingo K. Mellinghoff, MD, on Glioma: Phase III Results on Vorasidenib

Lisa A. Carey, MD, and Javier Cortes, MD, PhD, on HER2-Positive Early Breast Cancer: Chemotherapy De-escalation Under Study in PHERGain Trial

Narjust Florez, MD, and Heather A. Wakelee, MD, on Early-Stage NSCLC: Phase III Findings From KEYNOTE-671 on Pembrolizumab and Platinum-Based Chemotherapy

Jennifer L. Crombie, MD, on DLBCL: Real-World Outcomes With Novel Therapies in Relapsed or Refractory Disease

Jonathan W. Riess, MD, on EGFR-Mutated Non–Small Cell Lung Cancer: What’s Next?

Jason J. Luke, MD, on Melanoma Adjuvant Therapy: Final Analysis of KEYNOTE-716

Sarah K. Tasian, MD, on Hematologic Malignancies in Children: Expert Commentary

Arlene O. Siefker-Radtke, MD, on Metastatic Urothelial Carcinoma: New Data on Erdafitinib vs Chemotherapy From the THOR Study

Penelope Bradbury, MBChB, on Pleural Mesothelioma: New Results From the IND227 Trial of Cisplatin and Pemetrexed With or Without Pembrolizumab

Alicia K. Morgans, MD, MPH, and Praful Ravi, MRCP, MBBChir, on Localized Prostate Cancer: Prognostic Impact of PSA Nadir

Arlene O. Siefker-Radtke, MD, on Metastatic Urothelial Carcinoma: New Data on Erdafitinib and Cetrelimab From the NORSE Study

Cathy Eng, MD, and Lars Henrik Jensen, MD, PhD, on Locally Advanced Colon Cancer: Efficacy of Neoadjuvant Chemotherapy and Standard Treatment

Smitha Krishnamurthi, MD, and Deb Schrag, MD, MPH, on Rectal Cancer: New Findings on Chemoradiation, Chemotherapy, and Excision

Allison Betof Warner, MD, PhD, and Zeynep Eroglu, MD, on Metastatic Melanoma: New Data on Dabrafenib, Trametinib, and Navitoclax

James Chih-Hsin Yang, MD, PhD, on Metastatic Nonsquamous NSCLC: Evaluating Pemetrexed and Platinum With or Without Pembrolizumab

Tycel J. Phillips, MD, and Emanuele Zucca, MD, on Primary Mediastinal B-Cell Lymphoma: New Data on Observation vs Radiotherapy

Alicia K. Morgans, MD, MPH, and Karim Fizazi, MD, on Prostate Cancer: Phase III Results on Talazoparib Plus Enzalutamide as First-Line Treatment

Narjust Florez, MD, and Ticiana Leal, MD, on Metastatic NSCLC: Tumor Treating Fields Therapy After Platinum Resistance

Jennifer A. Woyach, MD, on New Findings on CLL, COVID-19, and Treatment With Obinutuzumab Plus Venetoclax

Cathy Eng, MD, and Thejus Jayakrishnan, MD, on Colorectal Cancer: Metabolomic Differences in Young-Onset vs Average-Onset Disease

Rami Manochakian, MD, on NSCLC: Commentary on the ADAURA Trial of Osimertinib

Narjust Florez, MD, and Ferdinandos Skoulidis, MD, PhD, on NSCLC: Findings on Sotorasib vs Docetaxel in the CodeBreaK 200 Trial

Reid Merryman, MD, on High-Risk Follicular Lymphoma: New Data on Epcoritamab, Rituximab, and Lenalidomide

Clifford A. Hudis, MD, on ASCO 2023 Perspectives: The Power of Connecting and Collaborating

Shailender Bhatia, MD, on Merkel Cell Carcinoma: Results From CheckMate 358 on Nivolumab With or Without Ipilimumab

Carmen E. Guerra, MD, MSCE, on Diversity, Equity, and Inclusion in Clinical Trials: Expert Commentary

Aaron T. Gerds, MD, on Anemia in Myelofibrosis: New Data on Treatment With Luspatercept

Ajay K. Nooka, MBBS, on High-Risk Myeloma: Data on Carfilzomib, Pomalidomide, and Dexamethasone

Ajay K. Nooka, MBBS, Relapsed or Refractory Multiple Myeloma: Efficacy and Safety Data for Elranatamab


2023 Society of Surgical Oncology International Conference on Surgical Cancer Care

Judy C. Boughey, MD, on Changes in Axillary Surgical Management: An I-SPY2 Analysis

Kari M. Rosenkranz, MD, on Breast Cancer: Impact of Breast Conservation on Local Recurrence

Anita Mamtani, MD, on Axillary Dissection: For What Types of Breast Cancer Can It Be Avoided?

Advertisement

Advertisement




Apr
26
Today In Oncology
FDA Approves Lu-177 Dotatate for Pediatric Patients With GEP-NETs
AI Model May Help Predict Treatment Responses Select Most Effective Cancer Therapies in Patients With Cancer
In-Hospital Mortality Among Patients With COVID-19 Infection, With or Without Cancer
Imaging Drug to Assist in Detection of Cancerous Tissue Following Lumpectomy Approved
Potential Protective Effects of Aspirin Against Colorectal Cancer
View More 
Advertisement
© 2024 HSP News Service, L.L.C.
Designed by Harborside